OpenClinica, LLC has announced that Rockville, MD-based KAI Research, Inc., (KAI), an Altarum Company, has selected the OpenClinica Enterprise Edition to power Phase I – IV clinical trials. Founded in 1986, KAI is a full service contract research organization (CRO) that provides innovative, cost-effective, and practical support to pharmaceutical, biotech and academic institutions, and the National Institutes of Health (NIH).
The OpenClinica software enhances clinical trials by streamlining electronic data capture (EDC) and clinical data management. The result is higher quality and faster access to the data.
“KAI is a CRO that relies on cutting edge information technology to help deliver the greatest value to our clients,” states Patti Shugarts, chief operating officer at KAI. She continues: “OpenClinica’s powerful technology and flexible model enable us to deploy a cutting edge EDC that meets the needs of both our industry and government clients.”
The OpenClinica clinical trial software is provided under a commercial open source model, and available in two editions. The OpenClinica Community Edition software is freely available under a widely accepted open source license. The OpenClinica Enterprise Edition consists of a fully validated version of the open source technology with additional capabilities, services, and resource ideal for mission critical research and highly regulated environments. The OpenClinica software is currently in use at over 500 biopharma sponsors, CROs, academic centers, and government agencies worldwide.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.